

Agnès Fournier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1619480/publications.pdf>

Version: 2024-02-01

111
papers

8,361
citations

81900

39
h-index

46799

89
g-index

120
all docs

120
docs citations

120
times ranked

11331
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults. JAMA Internal Medicine, 2016, 176, 816.	5.1	1,000
2	Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118â€™964 women with breast cancer from 117 epidemiological studies. Lancet Oncology, The, 2012, 13, 1141-1151.	10.7	753
3	Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Research and Treatment, 2007, 107, 103-111.	2.5	532
4	Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocrine-Related Cancer, 2005, 12, 1071-1082.	3.1	435
5	Serum Sex Steroids in Premenopausal Women and Breast Cancer Risk Within the European Prospective Investigation into Cancer and Nutrition (EPIC). Journal of the National Cancer Institute, 2005, 97, 755-765.	6.3	391
6	Trajectories of Depressive Symptoms Before Diagnosis of Dementia. JAMA Psychiatry, 2017, 74, 712.	11.0	361
7	Breast cancer risk in relation to different types of hormone replacement therapy in the E3Nâ€™EPIC cohort. International Journal of Cancer, 2005, 114, 448-454.	5.1	338
8	Physical activity and all-cause mortality across levels of overall and abdominal adiposity in European men and women: the European Prospective Investigation into Cancer and Nutrition Study (EPIC). American Journal of Clinical Nutrition, 2015, 101, 613-621.	4.7	284
9	Postmenopausal Hormone Therapy and Risk of Idiopathic Venous Thromboembolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 340-345.	2.4	233
10	Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2010, 127, 442-451.	5.1	223
11	Postmenopausal Breast Cancer Risk and Dietary Patterns in the E3N-EPIC Prospective Cohort Study. American Journal of Epidemiology, 2009, 170, 1257-1267.	3.4	171
12	Dietary Lignan Intake and Postmenopausal Breast Cancer Risk by Estrogen and Progesterone Receptor Status. Journal of the National Cancer Institute, 2007, 99, 475-486.	6.3	166
13	Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. British Journal of Cancer, 2011, 105, 1436-1442.	6.4	160
14	Use of Different Postmenopausal Hormone Therapies and Risk of Histology- and Hormone Receptorâ€™Defined Invasive Breast Cancer. Journal of Clinical Oncology, 2008, 26, 1260-1268.	1.6	156
15	Interactions Between Genetic Variants and Breast Cancer Risk Factors in the Breast and Prostate Cancer Cohort Consortium. Journal of the National Cancer Institute, 2011, 103, 1252-1263.	6.3	147
16	Physical Activity and Breast Cancer Risk: The European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 36-42.	2.5	127
17	Menopausal hormone therapy and breast cancer risk: Impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2011, 128, 144-156.	5.1	125
18	Estrogen-Progestagen Menopausal Hormone Therapy and Breast Cancer: Does Delay From Menopause Onset to Treatment Initiation Influence Risks?. Journal of Clinical Oncology, 2009, 27, 5138-5143.	1.6	123

#	ARTICLE	IF	CITATIONS
19	Menopausal Hormone Therapy and Risk of Endometrial Carcinoma Among Postmenopausal Women in the European Prospective Investigation into Cancer and Nutrition. <i>American Journal of Epidemiology</i> , 2010, 172, 1394-1403.	3.4	117
20	Alcohol intake and breast cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). <i>Cancer Causes and Control</i> , 2007, 18, 361-373.	1.8	104
21	Long-Term Exposure to Ambient Air Pollution and Incidence of Postmenopausal Breast Cancer in 15 European Cohorts within the ESCAPE Project. <i>Environmental Health Perspectives</i> , 2017, 125, 107005.	6.0	104
22	The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort. <i>PLoS ONE</i> , 2016, 11, e0147029.	2.5	102
23	Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. <i>Breast Cancer Research</i> , 2012, 14, R76.	5.0	94
24	EPIC-Heart: The cardiovascular component of a prospective study of nutritional, lifestyle and biological factors in 520,000 middle-aged participants from 10 European countries. <i>European Journal of Epidemiology</i> , 2007, 22, 129-141.	5.7	91
25	Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 535-543.	2.5	82
26	Postmenopausal hormone therapy and asthma onset in the E3N cohort. <i>Thorax</i> , 2010, 65, 292-297.	5.6	80
27	Prospective analysis of circulating metabolites and breast cancer in EPIC. <i>BMC Medicine</i> , 2019, 17, 178.	5.5	79
28	Risks of Endometrial Cancer Associated With Different Hormone Replacement Therapies in the E3N Cohort, 1992-2008. <i>American Journal of Epidemiology</i> , 2014, 180, 508-517.	3.4	76
29	Reproductive factors and risk of hormone receptor positive and negative breast cancer: a cohort study. <i>BMC Cancer</i> , 2013, 13, 584.	2.6	74
30	Physical activity and risk of breast cancer overall and by hormone receptor status: The European prospective investigation into cancer and nutrition. <i>International Journal of Cancer</i> , 2013, 132, 1667-1678.	5.1	72
31	Physical Activity and Ovarian Cancer Risk: the European Prospective Investigation into Cancer and Nutrition. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 351-354.	2.5	70
32	Risk factors for onset of menopausal symptoms. <i>Maturitas</i> , 2008, 60, 108-121.	2.4	69
33	Reproductive and menstrual factors and risk of differentiated thyroid carcinoma: The EPIC study. <i>International Journal of Cancer</i> , 2015, 136, 1218-1227.	5.1	69
34	Anthropometric measures and epithelial ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition. <i>International Journal of Cancer</i> , 2010, 126, 2404-2415.	5.1	68
35	Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle GÄ©nÄ©rale de lâ€™Education Nationale (E3N) cohort. <i>Diabetologia</i> , 2009, 52, 2092-2100.	6.3	64
36	Association between physical activity and risk of hepatobiliary cancers: A multinational cohort study. <i>Journal of Hepatology</i> , 2019, 70, 885-892.	3.7	58

#	ARTICLE	IF	CITATIONS
37	Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. <i>Cancer Causes and Control</i> , 2011, 22, 1075-1084.	1.8	51
38	Oral contraceptives, reproductive history and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition. <i>British Journal of Cancer</i> , 2010, 103, 1755-1759.	6.4	46
39	Adipokines and inflammation markers and risk of differentiated thyroid carcinoma: The EPIC study. <i>International Journal of Cancer</i> , 2018, 142, 1332-1342.	5.1	42
40	Polymorphisms of genes coding for ghrelin and its receptor in relation to anthropometry, circulating levels of IGF-I and IGFBP-3, and breast cancer risk: a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). <i>Carcinogenesis</i> , 2008, 29, 1360-1366.	2.8	39
41	Associations Between Migraine and Type 2 Diabetes in Women. <i>JAMA Neurology</i> , 2019, 76, 257.	9.0	39
42	Estimate of deaths due to valvular insufficiency attributable to the use of benfluorex in France. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 343-351.	1.9	37
43	Oral progestagens before menopause and breast cancer risk. <i>British Journal of Cancer</i> , 2007, 96, 841-844.	6.4	36
44	Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition. <i>International Journal of Cancer</i> , 2015, 136, 399-410.	5.1	36
45	Recent Recreational Physical Activity and Breast Cancer Risk in Postmenopausal Women in the E3N Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1893-1902.	2.5	35
46	Menopausal hormone therapy and risk of cholecystectomy: a prospective study based on the French E3N cohort. <i>Cmaj</i> , 2013, 185, 555-561.	2.0	34
47	Personal History of Endometriosis and Risk of Cutaneous Melanoma in a Large Prospective Cohort of French Women. <i>Archives of Internal Medicine</i> , 2007, 167, 2061.	3.8	32
48	Menopausal hormone therapy and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition. <i>International Journal of Cancer</i> , 2011, 128, 1881-1889.	5.1	28
49	Endometrial cancer risk prediction including serum-based biomarkers: results from the EPIC cohort. <i>International Journal of Cancer</i> , 2017, 140, 1317-1323.	5.1	28
50	Ovarian cancer risk factors by tumor aggressiveness: An analysis from the Ovarian Cancer Cohort Consortium. <i>International Journal of Cancer</i> , 2019, 145, 58-69.	5.1	28
51	A treelet transform analysis to relate nutrient patterns to the risk of hormonal receptor-defined breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). <i>Public Health Nutrition</i> , 2016, 19, 242-254.	2.2	26
52	Added Value of Serum Hormone Measurements in Risk Prediction Models for Breast Cancer for Women Not Using Exogenous Hormones: Results from the EPIC Cohort. <i>Clinical Cancer Research</i> , 2017, 23, 4181-4189.	7.0	26
53	Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts. <i>Breast Cancer Research</i> , 2018, 20, 147.	5.0	24
54	Menopausal hormone therapy and risks of colorectal adenomas and cancers in the French E3N prospective cohort: true associations or bias?. <i>European Journal of Epidemiology</i> , 2012, 27, 439-452.	5.7	22

#	ARTICLE	IF	CITATIONS
55	Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort. <i>British Journal of Cancer</i> , 2015, 112, 162-166.	6.4	21
56	Oral contraceptive use and cutaneous melanoma risk: a French prospective cohort study. <i>International Journal of Cancer</i> , 2018, 143, 2390-2399.	5.1	21
57	Postmenopausal hormone therapy initiation before and after the Women's Health Initiative in two French cohorts. <i>Menopause</i> , 2011, 18, 219-223.	2.0	21
58	Progestagens Use Before Menopause and Breast Cancer Risk According to Histology and Hormone Receptors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 2723-2728.	2.5	19
59	Vitamin C supplement intake and postmenopausal breast cancer risk: interaction with dietary vitamin C. <i>American Journal of Clinical Nutrition</i> , 2016, 104, 228-234.	4.7	18
60	Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation. <i>International Journal of Cancer</i> , 2018, 143, 515-526.	5.1	18
61	Results from the European Prospective Investigation into Cancer and Nutrition Link Vitamin B6 Catabolism and Lung Cancer Risk. <i>Cancer Research</i> , 2018, 78, 302-308.	0.9	18
62	Adherence to the World Cancer Research Fund/American Institute for Cancer Research cancer prevention recommendations and risk of in situ breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. <i>BMC Medicine</i> , 2019, 17, 221.	5.5	18
63	Risk of Osteoporotic Fractures After Discontinuation of Menopausal Hormone Therapy: Results From the E3N Cohort. <i>American Journal of Epidemiology</i> , 2011, 174, 12-21.	3.4	17
64	Multimorbidity medications and poor asthma prognosis. <i>European Respiratory Journal</i> , 2018, 51, 1702114.	6.7	17
65	Use of dietary supplements containing soy isoflavones and breast cancer risk among women aged >50Å: a prospective study. <i>American Journal of Clinical Nutrition</i> , 2019, 109, 597-605.	4.7	17
66	Postmenopausal hormone use and cutaneous melanoma risk: A French prospective cohort study. <i>International Journal of Cancer</i> , 2019, 145, 1754-1767.	5.1	16
67	Previous oral contraceptive use and breast cancer risk according to hormone replacement therapy use among postmenopausal women. <i>Cancer Causes and Control</i> , 2005, 16, 537-544.	1.8	14
68	Prospective Study on Physical Activity and Risk of In Situ Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 2209-2219.	2.5	14
69	Mediation analysis of the alcohol-postmenopausal breast cancer relationship by sex hormones in the EPIC cohort. <i>International Journal of Cancer</i> , 2020, 146, 759-768.	5.1	14
70	Exogenous hormone use and cutaneous melanoma risk in women: The European Prospective Investigation into Cancer and Nutrition. <i>International Journal of Cancer</i> , 2020, 146, 3267-3280.	5.1	14
71	Use of Bisphosphonates and Risk of Breast Cancer in a French Cohort of Postmenopausal Women. <i>Journal of Clinical Oncology</i> , 2017, 35, 3230-3239.	1.6	13
72	Use of nonsteroidal anti-inflammatory drugs and breast cancer risk in a prospective cohort of postmenopausal women. <i>Breast Cancer Research</i> , 2020, 22, 118.	5.0	13

#	ARTICLE	IF	CITATIONS
73	Association between Melanocytic Nevi and Risk of Breast Diseases: The French E3N Prospective Cohort. <i>PLoS Medicine</i> , 2014, 11, e1001660.	8.4	12
74	Postmenopausal breast cancer risk and interactions between body mass index, menopausal hormone therapy use, and vitamin D supplementation: Evidence from the E3N cohort. <i>International Journal of Cancer</i> , 2016, 139, 2193-2200.	5.1	12
75	Risk of asthma onset after natural and surgical menopause: Results from the French E3N cohort. <i>Maturitas</i> , 2018, 118, 44-50.	2.4	12
76	Interaction between current vitamin D supplementation and menopausal hormone therapy use on breast cancer risk: evidence from the E3N cohort. <i>American Journal of Clinical Nutrition</i> , 2015, 102, 966-973.	4.7	11
77	Use of benzodiazepines and cardiovascular mortality in a cohort of women aged over 50 years. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1475-1484.	1.9	11
78	Nonsteroidal anti-inflammatory drug use and breast cancer risk in a European prospective cohort study. <i>International Journal of Cancer</i> , 2018, 143, 1688-1695.	5.1	11
79	Physical activity, sex steroid, and growth factor concentrations in pre- and post-menopausal women: a cross-sectional study within the EPIC cohort. <i>Cancer Causes and Control</i> , 2014, 25, 111-124.	1.8	10
80	Menopausal hormone therapy and risk of incident hypertension: role of the route of estrogen administration and progestogens in the E3N cohort. <i>Menopause</i> , 2021, 28, 1204-1208.	2.0	10
81	Receptor activator of nuclear factor κ B ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort. <i>BMC Cancer</i> , 2018, 18, 1010.	2.6	9
82	Predicting Circulating CA125 Levels among Healthy Premenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1076-1085.	2.5	9
83	Use of systemic glucocorticoids and risk of breast cancer in a prospective cohort of postmenopausal women. <i>BMC Medicine</i> , 2021, 19, 186.	5.5	9
84	Should transdermal rather than oral estrogens be used in menopausal hormone therapy?: a review. <i>Menopause International</i> , 2010, 16, 23-32.	1.6	8
85	Health characteristics of women beginning postmenopausal hormone therapy. <i>Menopause</i> , 2014, 21, 687-693.	2.0	8
86	Reproductive and Lifestyle Factors and Circulating sRANKL and OPG Concentrations in Women: Results from the EPIC Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1746-1754.	2.5	8
87	Endogenous Circulating Sex Hormone Concentrations and Colon Cancer Risk in Postmenopausal Women: A Prospective Study and Meta-Analysis. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab084.	2.9	8
88	Breast Cancer and Hormonal Therapy in Postmenopausal Women. <i>New England Journal of Medicine</i> , 2009, 360, 2366-2367.	27.0	6
89	Characteristics and recent evolution of menopausal hormone therapy use in a cohort of Swedish women. <i>Climacteric</i> , 2009, 12, 410-418.	2.4	6
90	Reproductive Factors, Exogenous Hormone Use, and Risk of B-Cell Non-Hodgkin Lymphoma in a Cohort of Women From the European Prospective Investigation Into Cancer and Nutrition. <i>American Journal of Epidemiology</i> , 2019, 188, 274-281.	3.4	6

#	ARTICLE	IF	CITATIONS
91	Antiplatelet Drug Use and Breast Cancer Risk in a Prospective Cohort of Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 643-652.	2.5	5
92	Colorectal cancer risk following appendectomy: a pooled analysis of three large prospective cohort studies. <i>Cancer Communications</i> , 2022, 42, 486-489.	9.2	5
93	Differential Dietary Nutrient Intake according to Hormone Replacement Therapy Use: An Underestimated Confounding Factor in Epidemiologic Studies?. <i>American Journal of Epidemiology</i> , 2007, 166, 1451-1460.	3.4	4
94	Risk of onset of menopausal symptoms in periods surrounding menopause. <i>Maturitas</i> , 2007, 58, 340-347.	2.4	4
95	Increased risk of type 2 diabetes in antidepressant users: evidence from a 6-year longitudinal study in the E3N cohort. <i>Diabetic Medicine</i> , 2020, 37, 1866-1873.	2.3	4
96	Statin Use and Skin Cancer Risk: A Prospective Cohort Study. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1318-1325.e5.	0.7	4
97	Asthma Medication Ratio Phenotypes in Elderly Women. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 897-906.e5.	3.8	3
98	Menstrual Factors, Reproductive History, Hormone Use, and Urothelial Carcinoma Risk: A Prospective Study in the EPIC Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1654-1664.	2.5	3
99	Association between menopausal hormone therapy, mammographic density and breast cancer risk: results from the E3N cohort study. <i>Breast Cancer Research</i> , 2021, 23, 47.	5.0	3
100	Association between cardiovascular risk-factors and venous thromboembolism in a large longitudinal study of French women. <i>Thrombosis Journal</i> , 2021, 19, 58.	2.1	3
101	The impact of historical breastfeeding practices on the incidence of cancer in France in 2015. <i>Cancer Causes and Control</i> , 2018, 29, 325-332.	1.8	2
102	Premenopausal Use of Progestogens and Cutaneous Melanoma Risk: A French Prospective Cohort Study. <i>American Journal of Epidemiology</i> , 2020, 189, 314-329.	3.4	2
103	Associations between smoking and blood-group, and the risk of dyslipidaemia amongst French women. <i>Scientific Reports</i> , 2021, 11, 14844.	3.3	2
104	Breast cancer in HRT use. <i>International Journal of Cancer</i> , 2005, 116, 999-999.	5.1	1
105	Unsuspected Consequences of the Adolescent Overweight Epidemic. <i>Pediatrics</i> , 2007, 120, 924-925.	2.1	1
106	Did the decrease in use of menopausal hormone therapy induce a decrease in the incidence of breast cancer in France (and elsewhere)?. <i>Revue D'Epidemiologie Et De Sante Publique</i> , 2008, 56, e8-e12.	0.5	1
107	Response to the letter by Deltour et al.. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 586-588.	1.9	1
108	Serum Sex Steroids in Premenopausal Women and Breast Cancer Risk Within the European Prospective Investigation Into Cancer and Nutrition (EPIC). <i>Journal of Urology</i> , 2006, 175, 250-250.	0.4	0

#	ARTICLE	IF	CITATIONS
109	Breast Cancer Risk in Relation to Different Types of Hormone Replacement Therapy: Update of the E3N Results. American Journal of Epidemiology, 2006, 163, S161-S161.	3.4	0
110	Hormone Replacement Therapy and Osteoporotic Fractures. American Journal of Epidemiology, 2006, 163, S175-S175.	3.4	0
111	Response to the letter by Acar. Pharmacoepidemiology and Drug Safety, 2012, 21, 1245-1246.	1.9	0